Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers

Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly...

Full description

Saved in:
Bibliographic Details
Main Authors: Xabier Mielgo-Rubio, Virginia Calvo, Javier Luna, Jordi Remon, Margarita Martín, Pedro Berraondo, José Ramón Jarabo, Oliver Higuera, Esther Conde, Javier De Castro, Mariano Provencio, Florentino Hernando Trancho, Fernando López-Ríos, Felipe Couñago
Format: Artigo
Language:Inglês
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
immunotherapy
early-stage
non-small cell lung cancer
biomarkers
PD-1
nivolumab
Online Access:https://www.mdpi.com/2072-6694/12/11/3459
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items